Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2001-07-20
2008-09-16
Navarro, Mark (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Reexamination Certificate
active
07425606
ABSTRACT:
Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).
REFERENCES:
patent: 2004/0086518 (2004-05-01), Zanetti
patent: WO 91/04045 (1991-04-01), None
patent: WO 95/27901 (1995-10-01), None
patent: WO 97/35193 (1997-09-01), None
patent: WO 00/02581 (2000-01-01), None
Plotkin et al (Vaccines W.B. Saunders Company 1988, p. 571).
Ezzell (J. NIH Res, vol. 7, pp. 46-49, 1995).
Spilter (Cancer Biotherapy vol. 10, pp. 1-3, 1995).
Boon (Adv. Can. Res. vol. 58, pp. 177-210, 1992).
Gura (Science vol. 278, pp. 1041-1042, 1997).
Lee et al (Journal of Immunology vol. 163, pp. 6292-6300, 1999).
Pogue et al., “Amino-terminal alternation of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity”,Proceedings of the National Academy of Sciences of the United States, vol. 92, No. 18, 1995, pp. 8166-8170.
Hudrisier et al., “Relative implication of peptide residues in binding to major histocompatibility complex class I, H-2D-b: Application to the design of high-affinity, allele-specific peptides”,Molecular Immunology, vol. 32, No. 122, 1995, pp. 895-907.
Oukka et al., “Protection against lethal viral infection by vaccination with nonimmunodominant peptides”,Journal of Medicine, vol. 157, No. 7, Oct. 1, 1996, pp. 3039-3045.
Tourdot et al., “Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination”,Journal of Immunology, vol. 159, No. 5, Sep. 1, 1997, pp. 2391-2398.
Gross Alexandre David
Kosmatopoulos Kostas
Scardino Antonio
Tourdot Sophie
Alston & Bird LLP
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale (Inser
Navarro Mark
LandOfFree
Method for screening peptides for use in immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for screening peptides for use in immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening peptides for use in immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973850